1. Home
  2. NKTX vs TNXP Comparison

NKTX vs TNXP Comparison

Compare NKTX & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$3.14

Market Cap

188.9M

Sector

Health Care

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$13.24

Market Cap

198.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKTX
TNXP
Founded
2015
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
188.9M
198.6M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
NKTX
TNXP
Price
$3.14
$13.24
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$11.33
N/A
AVG Volume (30 Days)
749.2K
383.6K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
11.88
91.75
EPS
N/A
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
N/A
$558.11
Revenue Next Year
N/A
$38.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.85
52 Week Low
$1.63
$11.60
52 Week High
$3.65
$69.65

Technical Indicators

Market Signals
Indicator
NKTX
TNXP
Relative Strength Index (RSI) 58.80 48.43
Support Level $1.88 $12.43
Resistance Level $3.35 $15.19
Average True Range (ATR) 0.21 1.17
MACD -0.01 -0.06
Stochastic Oscillator 74.00 28.69

Price Performance

Historical Comparison
NKTX
TNXP

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: